BHC N Panoramica delle azioni Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Bausch Health Companies Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Bausch Health Companies Prezzi storici delle azioni Prezzo attuale dell'azione US$150.72 Massimo di 52 settimane US$200.19 Minimo di 52 settimane US$108.01 Beta 0.69 Variazione di 1 mese -24.71% Variazione a 3 mesi n/a Variazione di 1 anno n/a Variazione a 3 anni -74.10% Variazione a 5 anni -73.13% Variazione dall'IPO -91.25%
Notizie e aggiornamenti recenti
Forecast breakeven date pushed back to 2025 Dec 11
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023) Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28 Vedi altri aggiornamenti
Forecast breakeven date pushed back to 2025 Dec 11
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023) Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Second quarter 2024 earnings released: EPS: US$0.03 (vs US$0.071 in 2Q 2023) Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Forecast breakeven date moved forward to 2024 Apr 01
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022) Feb 23
New major risk - Negative shareholders equity Feb 22
No longer forecast to breakeven Feb 22
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
New major risk - Financial position Jul 02
First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022) May 06
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Forecast breakeven date pushed back to 2025 Apr 26
Forecast breakeven date pushed back to 2025 Apr 18
Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021) Feb 24
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 14
Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada Sep 23
Insider recently sold Mex$14m worth of stock Sep 21 Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)
Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin Sep 10
Investor sentiment improved over the past week Sep 09
Investor sentiment deteriorated over the past week Aug 23 Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Second quarter 2022 earnings released: US$0.40 loss per share (vs US$1.66 loss in 2Q 2021) Aug 10 Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022
Insufficient new directors Jul 31
Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Insufficient new directors Jul 01
Bausch Health Companies Inc. Announces Updates to Its Board of Directors Jun 24
Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer Jun 01
Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022 May 12
Bausch Health Companies Inc. Announces Management Changes May 08
Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022 May 02
Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022 Apr 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26 Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022
Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE Feb 09
Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 04
Bausch Health Companies Inc. has filed an IPO. Jan 15
Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection Dec 23
Insider recently bought Mex$31m worth of stock Dec 03
Insufficient new directors Nov 24
Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.20 in 3Q 2020) Nov 04
Forecast to breakeven in 2022 Oct 30
Insufficient new directors Oct 30
Forecast to breakeven in 2022 Sep 23
Independent Director recently bought Mex$5.0m worth of stock Aug 07
Bausch Health Companies Inc. Revises Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: US$1.66 loss per share (vs US$0.92 loss in 2Q 2020) Aug 05
Abu Dhabi Developmental Holding Company PJSC completed the acquisition of Amoun Pharmaceutical Company S.A.E. from Bausch Health Companies Inc. (NYSE:BHC) and others. Aug 04
Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra® Multifocal for Astigmatism Contact Lenses Jun 24
Independent Director David Hale has left the company Jun 22
CFO & Executive VP recently sold Mex$11m worth of stock Jun 17
Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) Jun 03
Independent Director recently sold Mex$7.0m worth of stock May 30
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Four Scientific Poster Presentations Featuring Data for XIFAXAN May 18
Bausch Health Companies Inc. Announces New Data from the National Eye Reaffirms the Clinical Outcomes of the AREDS2 Study May 13
First quarter 2021 earnings released: US$1.71 loss per share (vs US$0.43 loss in 1Q 2020) May 07
Bausch Health Companies Inc. Reiterates Revenue Guidance for the Full Year of 2021 May 05 Rendimenti per gli azionisti BHC N MX Pharmaceuticals MX Mercato 7D -3.1% -0.4% -0.4% 1Y n/a -27.2% -14.8%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: Dati insufficienti per determinare come si è comportato BHC N rispetto al settore MX Pharmaceuticals.
Rendimento vs Mercato: Dati insufficienti per determinare la performance di BHC N rispetto al mercato MX.
Volatilità dei prezzi Is BHC N's price volatile compared to industry and market? BHC N volatility BHC N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.7%
Prezzo delle azioni stabile: Il prezzo delle azioni di BHC N è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di BHC N nell'ultimo anno.
Informazioni sull'azienda Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Sviluppa, produce e commercializza una serie di prodotti principalmente in gastroenterologia, epatologia, neurologia, dermatologia, prodotti farmaceutici internazionali, prodotti da banco (OTC), dispositivi medici estetici e salute degli occhi. L'azienda opera attraverso cinque segmenti: Salix, International, Solta Medical, Diversified e Bausch + Lomb.
Mostra di più Bausch Health Companies Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Bausch Health Companies con la sua capitalizzazione di mercato? BHC N statistiche fondamentali Capitalizzazione di mercato Mex$57.21b Guadagni(TTM ) -Mex$3.62b Ricavi(TTM ) Mex$192.64b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) BHC N Conto economico (TTM ) Ricavi US$9.47b Costo del fatturato US$2.76b Profitto lordo US$6.71b Altre spese US$6.89b Guadagni -US$178.00m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.48 Margine lordo 70.87% Margine di profitto netto -1.88% Rapporto debito/patrimonio netto -8,887.2%
Come si è comportato BHC N nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/28 13:24 Prezzo dell'azione a fine giornata 2024/12/23 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Bausch Health Companies Inc. è coperta da 46 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
Mostra 43 altri analisti 
